MannKind Corporation (MNKD) Stock Analysis

Free AI-powered analysis and research for MannKind Corporation stock

Sector: Healthcare

Analyze MannKind Corporation (MNKD) Stock

MannKind Corporation (MNKD) is a leading company in the Healthcare sector. Use StockIQ's free analysis tool to get comprehensive insights into MNKD stock performance, technical indicators, and AI-powered trading recommendations.

Get instant AI-powered analysis including technical indicators, fundamental analysis, risk assessment, and trading insights for MannKind Corporation stock.

📰 Latest Update

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Wed, July 29, 2026 at 10:30 AM UTC 4 min read

MannKind Corporation reported positive results from its Phase 1b INFLO-1 trial, demonstrating the safety and tolerability of its Nintedanib DPI formulation for treating idiopathic pulmonary fibrosis (IPF). This clinical validation of MannKind's dry powder inhaler technology is significant for investors as it may enhance the company's product pipeline and market potential in the respiratory disease sector, potentially leading to future revenue growth.

Read full article →

Why Analyze MannKind Corporation (MNKD) with StockIQ?

• ✅ Free AI-powered analysis of MannKind Corporation (MNKD) stock
• ✅ Real-time technical indicators for MannKind Corporation stock
• ✅ Comprehensive risk assessment for MNKD
• ✅ No credit card required

People also watch